Financial Contrast: Co-Diagnostics (NASDAQ:CODX) vs. Opus Genetics (NASDAQ:IRD)

Opus Genetics (NASDAQ:IRD) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and price targets for Opus Genetics and Co-Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	15	1	2.89
Co-Diagnostics	1	1	1	1	2.50

Opus Genetics presently has a consensus target price of $11.92, suggesting a potential upside of 130.18%. Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 7,037.57%. Given Co-Diagnostics’ higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Opus Genetics.

Insider & Institutional Ownership

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 2.3% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Opus Genetics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 2.85, indicating that its stock price is 185% more volatile than the S&P 500.

Profitability

This table compares Opus Genetics and Co-Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

Earnings and Valuation

This table compares Opus Genetics and Co-Diagnostics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	30.15	-$49.59 million	($1.35)	-3.84
Co-Diagnostics	$721,386.00	9.15	-$46.90 million	($10.32)	-0.09

Co-Diagnostics has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

Opus Genetics beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.